SKI V

CAS No. 24418-86-8

SKI V( —— )

Catalog No. M21983 CAS No. 24418-86-8

SKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 215 In Stock
5MG 188 In Stock
10MG 297 In Stock
25MG 511 In Stock
50MG 732 In Stock
100MG 1079 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SKI V
  • Note
    Research use only, not for human use.
  • Brief Description
    SKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity
  • Description
    SKI V is a potent and noncompetitive non-lipid sphingosine kinase (SPHK; SK) inhibitor (GST-hSK,IC50 : 2 μM), and is a PI3K inhibitor(hPI3k,IC50 : 6 μM), induces apoptosis and has antitumor activity.
  • In Vitro
    SKI V has weak activity toward ERK2 (IC50 of 80 μM for hERK2) and does not inhibit PKC-α.SKI V (10 μM; for 24 hours) inhibits cancer cell proliferation and induces apoptosis. SKI V (0.2, 1, 5 μM; pretreated for 1 hour) decreases phospho-Akt and phospho-MEK levels. Near-confluent cultures of JC cells are serum-starved for 16 hours, followed by pretreatment SKI V for 1 hour. SKI V has IC50s for inhibition of sphingosine kinase (SK) and tumor cell proliferation of ~2 μM. SKI V (20 μg/ml) inhibits not only purified but endogenous SK in in MDA-MB-231 cells.SKI V (0.2, 1, 5 μM) inhibits intracellular S1P formation in JC cells in a dose-dependent fashion. Cell Proliferation Assay Cell Line:T24 tumor cells Concentration:10 μM Incubation Time:For 24 hours Result:Inhibited cancer cell proliferation.Apoptosis Analysis Cell Line:T24 tumor cells Concentration:10 μM Incubation Time:For 24 hours Result:Induced apoptosis.Western Blot AnalysisCell Line:JC cells Concentration:0.2, 1, 5 μM Incubation Time:Pretreated for 1 hour Result:Decreased phospho-Akt and phospho-MEK levels.
  • In Vivo
    SKI V (75 mg/kg; i.p.; days 1, 5, 9, 15) significantly lowers tumor growth (>50% decreased at day 18) than control animals. Animal Model:6-8 weeks old BALB/c female mice with JC mammary adenocarcinoma cellsDosage:75 mg/kg Administration:IP; days 1, 5, 9, 15 Result:Tumor growth was significantly lower (>50% decreased at day 18) than tumor growth in control animals.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    S1P Receptor
  • Recptor
    SphK|PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    24418-86-8
  • Formula Weight
    254.24
  • Molecular Formula
    C15H10O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (196.66 mM)
  • SMILES
    Oc1ccc(\C=C2\Oc3ccccc3C2=O)cc1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603.2. French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.
molnova catalog
related products
  • 4-Deoxypyridoxine hy...

    4-Deoxypyridoxine (hydrochloride) inhibits the degradation of intracellular S1P by inhibiting S1P lyase (SPL) activity, minimized the chemically induced apoptosis of insulinoma cell lines as S1P did.

  • W140 HBr

    [(3S)-3-amino-4-(3-hexylanilino)-4-oxobutyl]phosphonic acid;hydrobromide is a S1P1 antagonist with Ki of 2.84 μM.

  • MP-A08

    MP-A08 is a highly selective ATP competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 (Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively).